Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Dina Elharouni"'
Autor:
Heike Peterziel, Nora Jamaladdin, Dina ElHarouni, Xenia F. Gerloff, Sonja Herter, Petra Fiesel, Yannick Berker, Mirjam Blattner-Johnson, Kathrin Schramm, Barbara C. Jones, David Reuss, Laura Turunen, Aileen Friedenauer, Tim Holland-Letz, Martin Sill, Lena Weiser, Christopher Previti, Gnanaprakash Balasubramanian, Nicolas U. Gerber, Johannes Gojo, Caroline Hutter, Ingrid Øra, Olli Lohi, Antonis Kattamis, Bram de Wilde, Frank Westermann, Stephan Tippelt, Norbert Graf, Michaela Nathrath, Monika Sparber-Sauer, Astrid Sehested, Christof M. Kramm, Uta Dirksen, Olli Kallioniemi, Stefan M. Pfister, Cornelis M. van Tilburg, David T. W. Jones, Jani Saarela, Vilja Pietiäinen, Natalie Jäger, Matthias Schlesner, Annette Kopp-Schneider, Sina Oppermann, Till Milde, Olaf Witt, Ina Oehme
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-17 (2022)
Abstract The international precision oncology program INFORM enrolls relapsed/refractory pediatric cancer patients for comprehensive molecular analysis. We report a two-year pilot study implementing ex vivo drug sensitivity profiling (DSP) using a li
Externí odkaz:
https://doaj.org/article/d21634f309aa434aa0d7808304d8ec37
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Purpose: Osteonecrosis is a significant toxicity resulting from the treatment of pediatric Acute Lymphoblastic Leukemia (ALL). This study aimed to investigate the relationship between vitamin D receptor fok1 (VDR fok1) and thymidylate synthase (TYMS)
Externí odkaz:
https://doaj.org/article/26856596d81b45859db044a954d9cecc
Autor:
Yannick Berker, Dina ElHarouni, Heike Peterziel, Petra Fiesel, Olaf Witt, Ina Oehme, Matthias Schlesner, Sina Oppermann
Publikováno v:
IEEE Transactions on Medical Imaging. 41:3981-3999
Image-based phenotypic drug profiling is receiving increasing attention in drug discovery and precision medicine. Compared to classical end-point measurements quantifying drug response, image-based profiling enables both the quantification of drug re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::add49f6215a4fdfeae8a97e19417e7f7
https://doi.org/10.1109/tmi.2022.3205554
https://doi.org/10.1109/tmi.2022.3205554
Autor:
Matthew Nagy, Fiorella Schischlik, Kun Wang, Nishanth Ulhas Nair, E. Michael Gertz, Lipika R. Pal, Natalie Jaeger, Christopher Previti, Dina ElHarouni, Stefan M. Pfister, Eytan Ruppin
Publikováno v:
Cancer Research. 83:3118-3118
Introduction: PARP inhibitors (PARPi) are known to have a synthetic lethal (SL) relationship with BRCA1/2 mutated cancers (ie: BRCA loss confers sensitivity to PARPi), but heterogeneity in response exists. PARPi have also found utility in BRCA-non mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9b422b0cb4cd4acbd4bd47f11eba4e5
https://doi.org/10.1158/1538-7445.am2023-3118
https://doi.org/10.1158/1538-7445.am2023-3118
Autor:
Nora Jamaladdin, Heike Peterziel, Dina ElHarouni, Natalie Jäger, Tim Holland-Letz, Annette Kopp-Schneider, Romain Sigaud, Olaf Witt, Ina Oehme, Till Milde
Publikováno v:
Neuro-Oncology. 24:i33-i34
INTRODUCTION: The INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) study is a European pediatric precision oncology program. Using state of the art molecular assays, INFORM aims for identification of targetable genetic alteratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c186bd2f53a93a487900527a5f82af6c
https://doi.org/10.1093/neuonc/noac079.122
https://doi.org/10.1093/neuonc/noac079.122
Autor:
Olaf Witt, Sina Oppermann, Yannick Berker, Heike Peterziel, Sina Kreth, Matthias Schlesner, Ina Oehme, Dina ElHarouni, Vilja Pietiäinen, Laura Turunen, Apurva Gopisetty, Natalie Jäger, Sabine A. Stainczyk
Publikováno v:
Pharmacological research. 175
High throughput screening methods, measuring the sensitivity and resistance of tumor cells to drug treatments have been rapidly evolving. Not only do these screens allow correlating response profiles to tumor genomic features for developing novel pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c010be5e24e3c3a6b719fca4c33915
https://pubmed.ncbi.nlm.nih.gov/34848323
https://pubmed.ncbi.nlm.nih.gov/34848323
Autor:
Dina ElHarouni, Heike Peterziel, Kathrin Schramm, Till Milde, Sina Oppermann, Ina Oehme, Olaf Witt, Matthias Schlesner, Natalie Jäger
Publikováno v:
Journal of Clinical Oncology. 40:10036-10036
10036 Background: Within the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) registry over 1200 childhood malignancies were molecularly profiled using next generation sequencing to identify therapeutic targets. Nevertheless, hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b89cbac8161a0fc0299fbf0e1a66b021
https://doi.org/10.1200/jco.2022.40.16_suppl.10036
https://doi.org/10.1200/jco.2022.40.16_suppl.10036
Autor:
Ina Oehme, Thomas Hielscher, J Vollmer, Dina ElHarouni, Olaf Witt, Sina Oppermann, Till Milde, S Zeuner, Heike Peterziel, Jonas Ecker
Publikováno v:
Klinische Pädiatrie.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b86781ca48ebd0d2132f03d09a8e3b9
https://doi.org/10.1055/s-0040-1709805
https://doi.org/10.1055/s-0040-1709805
Autor:
Charlotte Gatzweiler, Johannes Ridinger, Sonja Herter, Xenia F. Gerloff, Dina ElHarouni, Yannick Berker, Roland Imle, Lukas Schmitt, Sina Kreth, Sabine Stainczyk, Simay Ayhan, Sara Najafi, Damir Krunic, Karen Frese, Benjamin Meder, David Reuss, Petra Fiesel, Kathrin Schramm, Mirjam Blattner-Johnson, David T. W. Jones, Ana Banito, Frank Westermann, Sina Oppermann, Till Milde, Heike Peterziel, Olaf Witt, Ina Oehme
Publikováno v:
Cancers; Volume 14; Issue 3; Pages: 849
Cancers, Vol 14, Iss 849, p 849 (2022)
Cancers, Vol 14, Iss 849, p 849 (2022)
The survival rate among children with relapsed tumors remains poor, due to tumor heterogeneity, lack of directly actionable tumor drivers and multidrug resistance. Novel personalized medicine approaches tailored to each tumor are urgently needed to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff12b95334a3e985de18262d9f0c2076
https://doi.org/10.3390/cancers14030849
https://doi.org/10.3390/cancers14030849
Autor:
Olaf Witt, Sina Oppermann, Ina Oehme, Jonas Ecker, Simon Zeuner, Till Milde, Romain Sigaud, Thomas Hielscher, Johanna Vollmer, Dina ElHarouni, Heike Peterziel
Publikováno v:
Neuro-Oncology. 23:i7-i8
Background Medulloblastoma (MB) is a highly aggressive brain tumour in children. Patients with Group 3 MB harbouring a MYC-amplification (subtype II) show a particularly poor outcome despite high-intensity multimodal therapy. We and others have previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed3b8fdddc12da60215250cdaa0fdf11
https://doi.org/10.1093/neuonc/noab090.029
https://doi.org/10.1093/neuonc/noab090.029